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Preventing sudden cardiac death (SCD) remains a major unsolved problem in contempo-
rary medical practice. As the most common cause of SCD, treatment for ventricular
arrhythmias is the target area of interest in research field. While implantable cardioverter-
defibrillator (ICD) effectively decreases death from ventricular arrhythmias in highly
selected patients, risk of inappropriate shocks, mortality from frequent therapy, chance of
failing in abortion of arrhythmias despite having a defibrillator, and our inability to
recognize which of several hundreds of thousands of patients at risk for sudden death but
do not meet current criteria for defibrillator, limit ICD effectiveness. In this article, a brief
review of mechanism leading to SCD, the existing evidence for a defibrillator and the
lacunae in present guidelines for patients clearly at risk for sudden death but without
proven benefit from a defibrillator are presented in Section I. Following this, interventional
approaches, both catheter-based and general measures that may serve as adjuncts to a
defibrillator in preventing this all too common catastrophic end event, are summarized in
Section II.
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prevalence of coronary artery disease, obesity and diabetes,
and the rise in the average age of the population.1 Further-
more, painful defibrillator discharges, relatively high inci-
dence of inappropriate ICD shocks, the cost of offering this
therapy to all patients potentially at risk for sudden death, and
the lack of effective methods to prevent the ventricular ar-
rhythmias that lead to sudden death are all contributory to
our very limited success to date.Fig. 1 e Major randomized trials performed that evaluated
efficacy of ICD therapy for reduction in
mortality (Reproduced with Permission from Europace).1.1. Etiology of SCD
An estimated 50%e70% of SCDs are due to lethal arrhythmias,
mainly those that are related to coronary artery disease.1e3
Ischemic heart disease has three major mechanisms for
placing a patient at risk of developing ventricular arrhyth-
mias. The first mechanism is related to acute coronary syn-
drome, which can result in ventricular fibrillation (VF) and
polymorphic ventricular tachycardia (VT). The second, which
can occur in a more “stable” state, is scar-related macro-
reentry, resulting in monomorphic VT, which is a major
mechanism of all ischemic heart patients. The third major
mechanism of VT is a reentrant circuit through the bundle
branch, though this accounts for less than 10% of VTs.4,5
Furthermore, focal, non-reentrant mechanisms are respon-
sible for less than 5%e10% of VTs.
Other patients can have VTs that are not related to coro-
nary artery disease. These are the non-ischemic cardiomy-
opathy (NICM) patients, which account for about 10%e15% of
SCD1,4 and the major mechanism at play is a scar-related
monomorphic VT. Finally, the remaining 5%e10% of SCD
are due to congenital cardiac conditions or in those with
apparent normal heart. For this later group, caution is
needed to identify idiopathic VT and vigorous searching for
other channel abnormalities may further identify underlying
mechanisms. Thus, the incidence of truly idiopathic VT may
be less than estimated. Furthermore, idiopathic VT is
thought to have more benign prognosis, although rare cases
may experience SCD. Idiopathic VF is another clinical entity
that poses high-risk for SCD. Taken all together, idiopathic
VF and rare cases of idiopathic VT may account for z5% of
SCD in all age groups.61.2. Primary prevention of SCD: the Use of ICDs
Several trials have shown that ICD implantation decreases
mortality and is currently the mainstay in SCD preventive
therapy in selected patients (Fig. 1).7 The largest trial con-
ducted in ischemic cardiomyopathy patients, the MADIT II
study, showed that ICD was associated with a 31% decrease in
mortality over 20 months, for an absolute decrease of 5.6%8
while the SCD-HeFT trial enrolling NICM patients found a
23% decrease inmortality over a 5-year period, for an absolute
decrease of 7.2% in primary prevention ICD implantation.9
Consequently, a dramatic increase in ICD prescriptions has
resulted in approximately 10,000 newly implanted de-
fibrillators a month in the United States, and almost 75% of
those were for primary prevention of SCD.101.3. Limitations of ICDs in prevention of SCD
Several limitations of the ICD device have been recognized.
For example, even though they are highly effective in abortion
of ventricular arrhythmias, ICDs do not prevent recurrent VT
episodes, and furthermore, the underlying arrhythmogenic
substrate remains unchanged or may even progress over
time.11 A pooled analysis of all randomized ICD trials indi-
cated an ICD-unresponsive SCD rate of 5%.12 Unfortunately,
the retrospective post-hoc analyses have not revealed any
distinguishing causes or characteristics of those who have
had ICD-unresponsive events. Moreover, the Oregon Sudden
Unexpected Death Study found that among ICD patients with
SCD, 17% of patients had VT/VF, suggesting failure of ICD
therapy to abort the lethal rhythm.13
Of great concern, firing of an ICD by itself can be associated
with increased mortality. This observation was found in both
appropriateand inappropriatedefibrillator shocks as shown ina
post-hoc analysis from the SCD-HeFT study.14 Poole,
et al showed data to suggest that an appropriate ICD shock is
associated with a six-fold increase in the risk of death whereas
an inappropriate ICD shockwas also associatedwith a two-fold
increase in the risk of death.14 Indeed, the incidence of inap-
propriate shocks is common and may be as high as 12%e30%,
while the incident-appropriate ICD shock is 20%e30% (Fig. 2).15
To reduce ICD therapy, optimal ICD programming has been
studied. The MADIT-RIT trial showed that a new stepwise ICD
programming results in an impressively low incidence of ICD
therapy (8% appropriate and 5% inappropriate therapy) during
1.4years follow-up.16Thisstrategyalso furtherdecreasesoverall
mortality. However, the aforementioned problems of ICD (i.e.
chance of recurrent ICD shock) still remain. In addition, ICD
implantation and therapy can negatively impact patients and
their families’ quality of life because of significant psychological
distress and depression since they have to adjust to the fact of
uncertain health conditions and potentially painful ICD shocks.2. Section II. Radiofrequency ablation to
prevent sudden death e can we do this?
Although radiofrequency ablation has been remarkably suc-
cessful in treating symptomatic arrhythmias of many
Fig. 2 e Comparison of Inappropriate versus Appropriate
ICD shocks in major randomized trials (Reproduced with
permission from JAMA).
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decrease the likelihood of sudden death has proved thus far a
nearly insurmountable challenge. VF and rapid VT e the most
malignant ventricular arrhythmias e are nearly impossible to
map because of hemodynamic instability. Further, the
arrhythmogenic substrate is a moving target with new areas
of abnormality and multiple abnormalities at any given time,
which have a propensity to give rise to a plethora of ventric-
ular tachycardias being common. Some advances recently,
however, have provided possibly some light at the end of this
tunnel. Percutaneous ventricular assist devices to provide
hemodynamic support and the concept of substrate mapping
and ablation (Fig. 3) are perhaps the most important ad-
vances.17 Substrate modification, however, is not a refined
science at present. The appropriate signals to target, the
ability to transmurally ablate abnormal substrate, and do so
without inducing dyssynchrony which in turn increases the
dynamicity of the substrate have not yet been established.18
In structural heart disease, including both ischemic and
non-ischemic cardiomyopathy, scar related reentry is the
major mechanism of monomorphic VT. The anatomic sub-
strate of scattered islands of surviving myocardial fibers
causes mismatched and slow conduction zones among the
scar tissue.19 This disruption in the conductive properties of
the ventricular syncytium can cause circuits to form leading
to origin of a ventricular arrhythmia. Sometimes these areas
are found through detection of low-amplitude,20 fractionated
electrograms that are recorded in these scar regions during
mapping and are targeted for substrate ablation, which is an
often-used method, as the majority of scar VT will have he-
modynamic instability, precluding mapping during prolonged
periods of sustained arrhythmia (Fig. 4).21 Besides focusing on
endocardium, other sites are of increasing interest in finding
abnormal substrates. For example, a damaged Purkinje sys-
tem can cause monomorphic PVC leading to more unstable
polymorphic VT and VF while ablation of bundle branch VT
reentry is also known to have high success rates. Further-
more, about 10%e15% of cases, especially in NICM, may comefrom epicardial areas that are not accessible with an endo-
cardial catheter.22
Polymorphic ventricular tachycardia and ventricular
fibrillation remains a greater challenge than even rapid VT. In
a portion of those cases, origin is often within the infrahisian
Purkinje system and we now know that ablation of triggered
VT and PVCs is associated with high success rates and
considered a potential curative therapy. However, our reso-
lution and ability to characterize arrhythmogenic fascicular
signals and distinguish these from myocardium signals is
at present rudimentary. Further, advances are needed in
ablation technology to target the arrhythmogenic fascicular
substrate without unnecessarily damaging functional
myocardium.
2.1. Survival benefit of VT ablation: available evidence
base
Della Bella et al. conducted a prospective study powered to
show survival benefits in those with successful VT ablation.23
They enrolled 528 patients with various structural heart dis-
eases (55% ischemic; 21% NICM) who experienced electrical
storm (9%), incessant VTs (25%) and recurrent paroxysmal VTs
(66%) for emergent or urgent VT ablation. After patients un-
derwent VT ablation, these were stratified according to
outcome of VT procedure and followed up: Group 1 was the
“successful group”, accounting for about 80% of patients who
had no inducible VT after ablation; Group 2 was comprised of
about10% of study patients and included those with inducible
but not clinically documented VT after ablation; and Group 3
included the remaining patients that still had inducible VT
after ablation. After 26 months of follow-up, patients with
successful VT ablation had significantly lower recurrence of
VTs (Group 1: 29%, Group 2: 40%, Group 3: 67%) and lower
cardiac death and SCD (Group 1: 8%, Group 2: 19%, and Group
3: 22%). Similarly, a large retrospective cohort composed of
208 patients with structural heart disease, ICDs and recurrent
VT showed that non-inducible VT after ablation was inde-
pendently associated with improved survival during a 3-year
follow-up.18 These data suggest that VT ablation has the
capability to reduce some recurrent VT and may improve
survival. However, comparison with other treatment modal-
ities and studies regarding standalone ablation are still
lacking.
2.2. Role of radiofrequency ablation for ventricular
tachycardia in ischemic cardiomyopathy patients
The benefit of prophylactic VT ablation to prevent appropriate
ICD shocks in patients who met the criteria for secondary
prevention ICD implantation has been demonstrated in two
multicenter randomized control trials for ischemic cardio-
myopathy patients. The SMASH-VT trial enrolled 128 patients,
including 18% with VF, who had a history of myocardial
infarction and met criteria for secondary prevention ICD
therapy.24 They were randomized into two groups either for
prophylactic VT ablation plus ICD versus only defibrillator
implantation. After 23 months, appropriate ICD shocks
occurredmore frequently in the ICD alone group (31%) than in
the combined ablation and ICD group (9%). There was also a
Fig. 3 e Use of Electro-Anatomic and Pace-Mapping Used to localize substrate responsible for Ventricular Tachycardia
Panels A and B show Electro-anatomic mapping in conjunction with Pacemapping techniques to localize VT substrate at
site of scar (Reproduced with permission from Circulation).
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in control vs. 9% in ablation groups), although it was not sta-
tistically significant. In the VTACH trial, a total of 107 patients
with a history of VT and ischemic cardiomyopathy were
enrolled for VT ablation.25 The results showed a 39% risk
reduction of ICD shocks compared to those with ICD alone.
However, there were no differences in all-cause mortality
between the two groups.
To date, prospective trials to examine the effectiveness of
VT ablation in preventing ICD shock have not been conducted
in patients who qualified for primary prevention ICD im-
plantation. However, available retrospective data from Hay-
ashi et al demonstrated promising ablative approach in suchcases.26 Based on their study of 38 primary prevention ICD
patients, appropriate ICD therapywas reduced from 65% to 5%
in those who underwent VT ablation.26 Collectedly, available
studies support that in both primary and secondary preven-
tion ICD groups, which underwent VT ablation had fewer ICD
shocks than those who did not receive ablation therapy.
However those studies were not able to show a benefit in
mortality from the procedure.
Reports from previous, non-randomized studies with the
end points of recurrent VT (not ICD shocks or mortality) also
showed promising effectiveness of ablation.21,27e29 Successful
VT ablation was achieved in 38%e95% of patients, with the
recurrent VT rate being approximately 13%e49% per year.21,23
Fig. 4 e Voltage guided mapping used to map and ablate VT substrate to reduce ICD shocks. Panels AeC show various
orientation of the heart, D shows site of ablation in the left ventricle (Reproduced with permission from Heart Failure Clinics).
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cool study.21 Nearly half of patients experienced recurrent VTs
during 6 months of follow-up in the setting of only 48% suc-
cessful ablation, supporting the hypothesis that successful
ablation results in long-term effective VT prevention. As
demonstrated in the most successful ablation rate from Della
Bella et al, above 80% of cases had no inducible VTs after
ablation and as low as 13% recurrent rate per year was found
during follow-up. It is important to note that this study was
conducted in a highly experienced ablation center.2.3. Non-ischemic cardiomyopathy
Ventricular arrhythmia is not as common in patients with
NICM (accounting for less than 5%) in comparison to the
ischemic population.3 There are no prospective, randomized
studies in this specific population. Furthermore, NICM is an
umbrella term including, but not limited to, dilated cardio-
myopathy (most common type), sarcoidosis, hypertrophic
cardiomyopathy, etc. Available studies often include many
subgroups of these non-ischemic patients. Thus, caution
is needed when applying the results to clinical practice,30,31
and more importantly, further studies in these specificpopulations must be done to establish best practices. Current
data shows that the success rates of VT ablation in patients
with dilated cardiomyopathy is 50%e74% at 1e2 years of
follow-up.31,32
There are some similarities in how we treat NICM patients
in terms of VT ablation for reduction of SCD or reduction of
ICD shocks (Fig. 4). In general, similar mapping principles for
post-infarction tachycardia are applied to VT ablation for
those with NICM because scar related macro-reentrant
mechanisms are common to both conditions. There are also
differences inherent to the characteristics of each disease
substrate; for example, in NICM the progression of myocardial
degeneration and fibrotic tissue may be a progressive pro-
cess.33 Thus, long-term efficacy of ablation is an important
investigation field that is in urgent need of further study in the
NICM population.2.4. Ventricular arrhythmia originating from the
conduction system
Bundle branch reentrant tachycardia accounts for 5%e8% of
monomorphic VT in structural heart disease patients.4,34
Antiarrhythmic therapy is usually ineffective in this setting.
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of ablation as high as 100%.5,35,36 As a result, catheter ablation
has long been a first-line treatment for bundle branch reen-
trant tachycardia and is given as a class I recommendation
from ACC/AHA/EUS guidelines and the EURA/HRS state-
ment.20,37 However, patients with bundle branch reentrant
tachycardia usually have extensive structural heart disease
with low ejection fractions, and thus these patients generally
receive ICD implantation as well.38
2.5. Other VT substrate
Clinical outcomes of VT ablation in other subsets are briefly
summarized here. In cases with absence of apparent struc-
tural heart disease, vigorous search for structural heart dis-
ease or other underlying electrical disorder is important since
this will direct next step of management. With continual
improvement in understanding of arrhythmic mechanism
and diagnostic tools, an increasing portion of patients are
subsequently have a diagnosis of specific disease, for instance
long QT syndrome, catecholamine polymorphic VT and Bru-
gada syndrome. After exclusion all of those, idiopathic VT is
likely assumed. This arrhythmia is generally has benign
prognosis and accounted for the minority of SCD. Thus a
cornerstone therapy is to control symptoms and medications
are first line treatment. Those with refractory or intolerant to
medical therapy are suitable for VT ablation since themajority
has inducible triggers from fascicular tract, right ventricular
outflow tract (in repetitive monomorphic VT) or posterior
septum (in idiopathic left VT). High rates of successful abla-
tion (60%e90% during an approximate 2 years follow-up).39,40
In Brugada syndrome and long QT syndromewhomanifest
with polymorphic VT/VF, triggers often originated from PVCs
or ectopy from right ventricular outflow tract, respectively. In
such cases, ablation of these foci yields high rate of success.41
Nonetheless, generally speaking in those conditions, ablation
is not the first line therapy. ICD implant is mostly required if
these patients present with aborted SCD. In more stable pa-
tients, treatment for Brugada syndrome remains controver-
sial, while beta-blocker is the first choice for long QT
syndrome.42
Lastly, patients who survive from idiopathic VF are
considered to have a high rate of recurrent SCD, thus ICD
therapy is recommended.7 Ablation is a therapeutic option if
stereotypic initiating PVC (often originated from the infra-
hisian Purkinje system) is recognized and if patients suffer
from repetitive ICD shocks.3. Section III. Interventional approaches
beyond ablation to prevent sudden cardiac death
Generally, reperfusion and complete revascularization are
urgently warranted in the setting of unstable ventricular ar-
rhythmias.37 In thosewith refractory and unstable conditions,
ventricular assist devices for either bridging to transplant or
destination therapy can be used as a life-saving therapy.
Unloading of pressure from both ventricles is thought to be an
effective mechanism. However, role of ventricular assist de-
vice implantation in treating refractory VT/VF remainscontroversial because the device itself may become a trigger
for ventricular arrhythmias.43
Autonomic modulation is postulated to reduce ventricular
tachyarrhythmias.
Mounting evidences show that increased sympathetic tone
plays an important role in SCD and genesis of ventricular ar-
rhythmias. Left cardiac sympathetic denervationwas found to
raise VF threshold.44 Thus, modulating the autonomic system
is an emerging therapy in this regard.45e51 First animalmodels
by Chen and colleagues demonstrated that after myocardial
infarction, increased sympathetic tone simulated stellate
ganglion discharge preceding the onset of VT/VF.52 Subse-
quent studies also showed that sympathetic activation pro-
longs QT interval and ventricular arrhythmias.53 The exact
mechanism how sympathetic nervous system promotes car-
diac arrhythmias is unclear, however it was postulated that
autonomic remodeling and hyper-innervated areas result in
heterogeneous electrical arrangement and prolongs action
potential while acute and large amount for neurotransmitters
may accentuate the excitability and refractoriness, increasing
susceptibility of arrhythmias.
A group of Dr. Nademanee enrolled 49 VF survivors for
symptomatic blockage (6 left stellate ganglionic blockade, 21
patients with infusion of propranolol or esmolol) compared to
standard treatment per the Advanced Cardiac Support. At 1-
week, 6 patients (22%) in sympathetic blockage died compared
to 18 deaths (82%) in the standard post-arrest care group
(death from VF was 3 and 18, respectively).44 Moreover, left
cardiac sympathetic denervation (LCSD) or left cervical stel-
late ganglionectomy was found to be an effective therapy in
reducing mortality in high-risk patients with long QT syn-
drome.54 Of the 147 patients, there were 48% SCD events
before the procedure compared to 16% with aborted cardiac
arrest plus 7% of sudden death after the procedure. Addi-
tionally, LCSD also effectively reduced life-threatening ar-
rhythmias catecholaminergic polymorphic VT in 3 case
reports.55 All had documented exercise induced VT, two had
recurrent syncope and one with cardiac arrest. All symptoms
were no longer present after LCSD. Of importance, in one case
with previous history of SCD, the patient was free from any
cardiac events after 30 years follow-up.
Similar results were found in reports from Bourke and
colleagues. In patients with VT storm and failure from anti-
arrhythmic and ablation, 6 of 8 patients who underwent
thoracic epidural anesthesia (TEA) and 5 of 9 patients who
underwent left cardiac sympathetic (or stellate) denervation
experienced significant reduction in arrhythmia burden.56
Overall, benefits seem to be immediate after the procedure
and without complications. The authors suggested that TEA
may provide transient and effective approach since it results
in complete sympathetic blockage by bilaterally blocking C8
through T4 segments proximal to both the left and right
stellate ganglions. This technique can be done at bedside by
local anesthesia, thus it is more feasible in unstable patients
and can be considered as bridging therapy for VT/VF storm.
Opposed to decrease sympathetic tone, parasympathetic
stimulation may protect against ventricular arrhythmias. As
summarized by Brack and authors, direct vagal stimuli pre-
vented risks of SCD in post myocardial infarction animal
models.57 Works by Issa et al found that thoracic spinal cord
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) s 1 2 0es 1 2 8S126stimulation in canine models with ongoing ischemia reduced
ventricular arrhythmias from 59% to 23%.50 However, the
modification of parasympathetic system has not been con-
ducted in human.
Other methods to interrupt sympathetic innervation have
been postulated. Few case reports with refractory VF under-
went successful renal denervation as a last resort, after failure
of ablation, ICD implant and antiarrhythmic drugs.58,59
Available data on one case report found that at 6 months, a
patient survived and was free from VT.58 Reduction of overall
norepinephrine level is thought to be one of its effective
mechanisms. Lastly, several novel treatment options are un-
derway such as that of successful percutaneous autonomic
neural modulation for atrial fibrillation, which may also open
a new approach for ventricular tachycardia.604. Future direction
Strategies to prevent SCD remain the most challenging field.
Firstly, methods to reduce ICD shock need to be emphasized.
In addition to stepwise defibrillator programming, VT ablation
seems to be promising. In order to confirm survival benefit,
larger prospective studies are required. With current evi-
dence, early transfer to an experienced center for VT ablation
should be recommended in secondary prevention ICD pa-
tients. However, this approach has not been tested in patients
with primary prevention ICD. Secondly, technological ad-
vances have made ablative therapy exciting, yet still refine-
ment and uniform consensus is required (for instance, how to
select appropriate patients, appropriate time of, definition of
successful VT ablation).11 Indeed, the efficacy of VT ablation
has not been consistent and data especially in patients with
NICM are limited.
Another exciting area of research and innovation involves
novel myocardial stimulation techniques and use of electro-
poration with low dose direct current and modulation of the
autonomic nervous system.60e625. Conclusion
Though the efficacy of VT/VF ablation techniques has
improved over time, SCDis still an unconquered frontier in
cardiac electrophysiology. To date, two randomized control
trials have shown that prophylactic VT ablation reduced ICD
therapy in secondary prevention patients. In polymorphic VTs
and VF, we now know that ablation of triggered PVCs is
associated with high success rates and considered a potential
curative therapy. However, this mechanism exists in only a
portion, but not all of VF. SCD therefore remains the leading
cause of death. Early recognition of patients at risk, use of
ICDs, possible advances in medical therapy, and the above-
reviewed ablative and non-ablative approaches may one day
put a dent into this large number of tragic loss of life.Conflicts of interest
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